$SVRA News

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041

Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Announces New Employment Inducement Grant

Savara Announces Chief Financial and Administrative Officer Transition

Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Assume Additional Role Of CFO

Savara: The Rare Disease Funnel Is Becoming A Commercial Asset

Savara Inc. (SVRA) Reports Q1 Financial Results

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International Conference

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Presents New Exercise Capacity Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP At ATS 2026 International Conference

Savara Reports First Quarter Financial Results and Provides Business Update

Savara Q1 EPS $(0.15) Misses $(0.14) Estimate

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim

Savara Announces New Employment Inducement Grant

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)